Hepion Pharmaceuticals, Inc. (CTRVP) — 8-K Filings

8-K Filings (22)

• Hepion Pharma Appoints New Officers, Clinical Data Expected Q3 — Jun 30, 2025 Risk: medium
  On June 25, 2025, Hepion Pharmaceuticals, Inc. announced changes to its board of directors and executive compensation. Dr. D. R. Ramakrishna was appointed as Ch
• Hepion Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 12, 2025 Risk: low
  Hepion Pharmaceuticals, Inc. filed an 8-K on June 12, 2025, to report on matters submitted to a vote of its security holders. The filing does not disclose speci
• Hepion Pharmaceuticals Announces Board and Compensation Changes — Jun 9, 2025 Risk: low
  Hepion Pharmaceuticals, Inc. announced on June 3, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depart
• Hepion Pharmaceuticals Enters Material Definitive Agreement — May 30, 2025 Risk: medium
  Hepion Pharmaceuticals, Inc. entered into a Material Definitive Agreement on May 26, 2025. The filing does not disclose the specific nature or counterparty of t
• Hepion Pharmaceuticals Faces Delisting Notice — May 12, 2025 Risk: high
  Hepion Pharmaceuticals, Inc. filed an 8-K on May 9, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The compan
• Hepion Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — May 6, 2025 Risk: medium
  Hepion Pharmaceuticals, Inc. announced on April 30, 2025, that it entered into a Material Definitive Agreement and also disclosed Unregistered Sales of Equity S
• Hepion Pharmaceuticals Faces Delisting Notice — Apr 17, 2025 Risk: high
  Hepion Pharmaceuticals, Inc. filed an 8-K on April 17, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The com
• Hepion Pharmaceuticals Faces Delisting Notice — Mar 20, 2025 Risk: high
  Hepion Pharmaceuticals, Inc. filed an 8-K on March 20, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, former
• Hepion Pharmaceuticals Files 8-K on Security Holder Rights — Mar 19, 2025 Risk: medium
  Hepion Pharmaceuticals, Inc. filed an 8-K on March 19, 2025, reporting material modifications to security holder rights and amendments to its articles of incorp
• Hepion Pharmaceuticals Files 8-K on Security Holder Vote — Mar 10, 2025 Risk: low
  Hepion Pharmaceuticals, Inc. filed an 8-K on March 10, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain speci
• Hepion Pharmaceuticals Files 8-K — Mar 4, 2025 Risk: low
  Hepion Pharmaceuticals, Inc. filed an 8-K on March 4, 2025, reporting on other events and financial statements. The company, formerly known as ContraVir Pharmac
• Hepion Pharmaceuticals Faces Delisting Notice — Jan 15, 2025 Risk: high
  Hepion Pharmaceuticals, Inc. filed an 8-K on January 15, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company was f
• Hepion Pharmaceuticals Terminates Material Agreement — Dec 11, 2024 Risk: medium
  On December 10, 2024, Hepion Pharmaceuticals, Inc. filed an 8-K report detailing the termination of a material definitive agreement. The filing also includes in
• Hepion Pharmaceuticals Fails Nasdaq Listing Standards — Nov 21, 2024 Risk: high
  Hepion Pharmaceuticals, Inc. received a notice on November 20, 2024, indicating it failed to meet the continued listing standards of The Nasdaq Stock Market LLC
• Hepion Pharmaceuticals Faces Nasdaq Delisting Warning — Sep 5, 2024 Risk: high
  Hepion Pharmaceuticals, Inc. announced on September 3, 2024, that it received a notification from The Nasdaq Stock Market indicating a failure to meet the minim
• Hepion Pharmaceuticals Board Changes and Officer Compensation — Aug 7, 2024 Risk: medium
  Hepion Pharmaceuticals, Inc. announced on August 5, 2024, a change in its board of directors. Specifically, Dr. Gregory J. Glenn has been appointed as a new dir
• Hepion Pharmaceuticals Files 8-K: Agreements, Equity Sales, Officer Changes — Jul 22, 2024 Risk: medium
  On July 19, 2024, Hepion Pharmaceuticals, Inc. entered into a material definitive agreement, likely related to financing or a significant business transaction.
• Hepion Pharmaceuticals Announces Executive and Board Changes — Mar 6, 2024 Risk: medium
  Hepion Pharmaceuticals, Inc. announced on March 5, 2024, a series of executive and board changes. Dr. D. Ashworth, previously Chief Medical Officer, has been ap
• Hepion Pharmaceuticals Announces Executive Leadership Changes — Feb 20, 2024 Risk: medium
  Hepion Pharmaceuticals, Inc. filed an 8-K on February 20, 2024, reporting on the departure of directors or certain officers, election of directors, appointment
• Hepion Pharma Sells Equity in Unregistered Offering — Feb 16, 2024 Risk: medium
  Hepion Pharmaceuticals, Inc. entered into a material definitive agreement on February 15, 2024, involving the unregistered sale of equity securities. This trans
• Hepion Pharma Appoints Dr. Todd Hobbs to Board of Directors — Feb 7, 2024
  Hepion Pharmaceuticals, Inc. (HEPA) announced on February 7, 2024, that Dr. Todd Hobbs was appointed as a Class I Director to its Board of Directors. Dr. Hobbs
• Hepion Pharma Changes Accountants, No Reason Disclosed — Jan 3, 2024
  Hepion Pharmaceuticals, Inc. (HEPA) announced on December 27, 2023, that it is changing its independent registered public accounting firm. This change is a rout

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX